Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,735Revenue $M9.8Net Margin (%)-4,825.6Altman Z-Score5.6
Enterprise Value $M1,604EPS $-4.3Operating Margin %-4,970.5Piotroski F-Score2
P/E(ttm)--Beneish M-Score-3.2Pre-tax Margin (%)-4,825.6Higher ROA y-yY
Price/Book10.510-y EBITDA Growth Rate %-4.9Quick Ratio4.7Cash flow > EarningsY
Price/Sales1,3935-y EBITDA Growth Rate %28.7Current Ratio4.7Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-62.1Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-73.8Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M41.5ROIC % (ttm)-462.5Gross Margin Increase y-yN

Gurus Latest Trades with SRPT

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
Current Price Change from Average Comment Current Shares
SRPTGeorge Soros 2014-12-31 Sold Out -0.05%$12.6 - $23.56
$ 41.79148%Sold Out0
SRPTGeorge Soros 2014-09-30 Reduce-0.08%$19.9 - $30.27
$ 41.7986%Reduce 52.21%325,000
SRPTGeorge Soros 2014-06-30 Add0.14%$22.18 - $38.91
$ 41.7932%Add 2620.00%680,000
SRPTGeorge Soros 2014-03-31 Reduce-0.04%$17.91 - $30.29
$ 41.7965%Reduce 89.27%25,000
SRPTGeorge Soros 2013-12-31 Reduce-0.22%$12.89 - $53.81
$ 41.7941%Reduce 64.98%233,000
SRPTGeorge Soros 2013-09-30 Add0.12%$30.906 - $47.97
$ 41.799%Add 56.28%665,274
SRPTGeorge Soros 2013-03-31 Add0.08%$23.97 - $36.95
$ 41.7945%Add 82.54%413,329
SRPTGeorge Soros 2012-12-31 Add0.05%$14.99 - $44.93
$ 41.7956%Add 184.13%226,429
SRPTFirst Eagle Investment 2012-03-31 Sold Out $4.44 - $9.6
$ 41.79542%Sold Out0
SRPTFirst Eagle Investment 2011-12-31 Reduce$3.24 - $6.54
$ 41.79743%Reduce 83.33%8,333
SRPTFirst Eagle Investment 2011-09-30 Add$6.3 - $9.9
$ 41.79432%Add 50.00%50,000
SRPTFirst Eagle Investment 2011-06-30 Buy $8.1 - $11.22
$ 41.79331%New holding33,333
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SRPT is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!

SRPT: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Kaye Edward M. MDSVP & Chief Medical Officer 2015-02-27Buy800$11.82253.55view
Christopher Nishan GarabedianPresident and CEO 2015-02-27Buy800$11.82253.55view
CHASE ANTHONY RDirector 2013-11-14Buy10,000$13.95199.57view
Aphale JayantSVP Technical Operations 2013-11-12Sell15,933$12.56232.72view
BEHRENS M KATHLEENDirector 2013-09-16Buy6,500$37.0412.82view
HODGMAN JOHNDirector 2013-09-03Sell5,556$34.9719.5view
CHASE ANTHONY RDirector 2013-08-22Buy3,500$32.6827.88view
Mahatme SandeshSenior Vice President, CFO 2013-08-20Buy5,000$31.134.37view
Price Ben GilDirector 2013-08-19Buy500$31.1834.03view
CHASE ANTHONY RDirector 2013-06-14Buy10,000$38.58.55view

Quarterly/Annual Reports about SRPT:

    News about SRPT:

    Articles On GuruFocus.com
    Sarepta Therapeutics Inc (SRPT) Will File NDA; Analysts Have Mixed Ratings May 20 2015 
    Wednesday’s Pre-Market Insights: Yahoo! Inc. (YHOO), Sarepta Therapeutics Inc (SRPT), Time Warner May 20 2015 
    Steven Cohen Keeps on Buying Biotechnological Companies May 04 2015 
    Ebola: Is The Cure Out There? Oct 14 2014 
    Insiders Are Buying Fate Therapeutics Oct 09 2013 
    comment on SRPT Mar 16 2013 
    comment on SRPT Mar 16 2013 
    comment on SRPT Feb 16 2013 

    More From Other Websites
    Sarepta Therapeutics Announces Proposed Public Offering of Common Stock Oct 05 2015
    Sarepta Therapeutics Announces Proposed Public Offering of Common Stock Oct 05 2015
    4:41 pm Sarepta Therapeutics to offer up to $125 mln of its common stock in an underwritten public... Oct 05 2015
    Sarepta: New Data Should Boost Stock Even Further Oct 02 2015
    Sarepta Unveils New Phase IIb Eteplirsen Data, Shares Soar Oct 02 2015
    ETF’s with exposure to Sarepta Therapeutics, Inc. : October 2, 2015 Oct 02 2015
    Sarepta Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : October 2, 2015 Oct 02 2015
    SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers Oct 01 2015
    Sarepta Therapeutics Announces Collaborative Research Agreement with Murdoch University Researchers... Oct 01 2015
    Sarepta Stock Soars On New Muscular-Dystrophy Data Oct 01 2015
    Sarepta Therapeutics Announces Collaborative Research Agreement with Murdoch University Researchers... Oct 01 2015
    What Do The World’s Greatest Investors Think of These Hot Biotech Stocks? Oct 01 2015
    Sarepta Therapeutics (SRPT) Stock Spikes on Duchenne Muscular Dystrophy Study Data Oct 01 2015
    Roth Cheers Latest Sarepta Data, Muscular Dystrophy Drug On Path To Approval Oct 01 2015
    Sarepta Therapeutics, Inc. Earnings Q2, 2015 Oct 01 2015
    Sarepta Makes Headway With Phase 2 Program Oct 01 2015
    ​Latest data from Cambridge’s Sarepta bodes well for FDA approval of Duchenne drug Oct 01 2015
    Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Oct 01 2015

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)